Department of Otolaryngology-Head and Neck Surgery, Stanford University School of Medicine, Stanford, California, U.S.A.
Aerodigestive and Airway Reconstruction Center, Lucile Packard Children's Hospital Stanford, Stanford, California, U.S.A.
Laryngoscope. 2021 Jun;131(6):E1941-E1949. doi: 10.1002/lary.29343. Epub 2021 Jan 6.
OBJECTIVES/HYPOTHESIS: The purpose of this study is to develop consensus on key points that would support the use of systemic bevacizumab for the treatment of recurrent respiratory papillomatosis (RRP), and to provide preliminary guidance surrounding the use of this treatment modality.
Delphi method-based survey series.
A multidisciplinary, multi-institutional panel of physicians with experience using systemic bevacizumab for the treatment of RRP was established. The Delphi method was used to identify and obtain consensus on characteristics associated with systemic bevacizumab use across five domains: 1) patient characteristics; 2) disease characteristics; 3) treating center characteristics; 4) prior treatment characteristics; and 5) prior work-up.
The international panel was composed of 70 experts from 12 countries, representing pediatric and adult otolaryngology, hematology/oncology, infectious diseases, pediatric surgery, family medicine, and epidemiology. A total of 189 items were identified, of which consensus was achieved on Patient Characteristics (9), Disease Characteristics (10), Treatment Center Characteristics (22), and Prior Workup Characteristics (18).
This consensus statement provides a useful starting point for clinicians and centers hoping to offer systemic bevacizumab for RRP and may serve as a framework to assess the components of practices and centers currently using this therapy. We hope to provide a strategy to offer the treatment and also to provide a springboard for bevacizumab's use in combination with other RRP treatment protocols. Standardized delivery systems may facilitate research efforts and provide dosing regimens to help shape best-practice applications of systemic bevacizumab for patients with early-onset or less-severe disease phenotypes.
5 Laryngoscope, 131:E1941-E1949, 2021.
目的/假设：本研究旨在就支持使用全身性贝伐珠单抗治疗复发性呼吸道乳头瘤病（RRP）的要点达成共识，并提供围绕这种治疗方式使用的初步指导。
基于德尔菲法的调查系列。
成立了一个具有使用全身性贝伐珠单抗治疗 RRP 经验的多学科、多机构医师的多学科、多机构小组。采用德尔菲法确定并就五个领域与全身性贝伐珠单抗使用相关的特征达成共识：1）患者特征；2）疾病特征；3）治疗中心特征；4）既往治疗特征；和 5）既往检查特征。
国际小组由来自 12 个国家的 70 名专家组成，代表小儿和成人耳鼻喉科、血液学/肿瘤学、传染病学、小儿外科、家庭医学和流行病学。共确定了 189 项内容，其中在患者特征（9 项）、疾病特征（10 项）、治疗中心特征（22 项）和既往检查特征（18 项）方面达成了共识。
本共识声明为希望为 RRP 提供全身性贝伐珠单抗的临床医生和中心提供了一个有用的起点，并可能成为评估当前使用该疗法的实践和中心的组成部分的框架。我们希望提供一种治疗策略，也为贝伐珠单抗与其他 RRP 治疗方案联合使用提供跳板。标准化的输送系统可能有助于研究工作，并提供剂量方案，以帮助塑造早期发病或疾病表型较轻的患者使用全身性贝伐珠单抗的最佳实践应用。
5 Laryngoscope, 131:E1941-E1949, 2021.
